This workshop will provide a practical introduction to positron emission tomography (PET) imaging. The basic physics and chemistry of PET will be presented, along with examples of its use in cancer, cardiovascular, and neurological research and patient management. The use of PET for diagnosis, staging, and treatment, in addition to monitoring of treatment will be discussed. Regulatory issues concerning the introduction of new PET imaging agents will be covered.
Our Fall Technologist Meeting is a one-day course designed especially for nuclear medicine technologists. We are only seeking VOICE credit (no other types of CEs). Attendees will gain up to seven VOICE credits for participating in this course.
NANETs/ SNMMI Symposium: Improvements in NET Imaging
Gallium-68-DOTA compounds that target somatostatin receptors have been used with PET to significantly improved the quality of imaging neuroendocrine tumors. Although approved in Europe, this class of agent has only been used in investigational trials under INDs in the US. Expanded efforts are underway to move them towards approval and into clinical practice. Recently, both 68Ga-DOTATOC and 68Ga-DOTATATE (GalioMedix ™) were granted orphan drug status by the FDA for the management of neuroendocrine tumors. These announcements have garnered widespread interest and elevated enthusiasm for using gallium imaging agents, but some issues related to using these agents remain unclear. Join David Dick, PhD, on Thursday, October 23 at 3:00pm ET, as he describes the current trials underway using the three Ga-68 DOTA agents (NOC/TATE/TOC) along with updates on the manufacturing, production and availability of the agents for clinical and/or investigational use.